A phase 1/2a dose-finding study and biomarker assessment of oral lisavanbulin in patients with high-grade glioma or glioblastoma

Lisavanbulin is a prodrug of the microtubule-targeting agent avanbulin. Both avanbulin and lisavanbulin have demonstrated significant antitumor activity in several preclinical tumor models including glioblastoma. Previous human studies demonstrated that 48-h infusions of intravenous lisavanbulin wer...

Full description

Saved in:

Bibliographic Details
Published in:	Cell reports. Medicine Vol. 6; no. 6; p. 102165
Main Authors:	Lopez, Juanita Suzanne, Haefliger, Simon, Plummer, Ruth, Clement, Paul M., Jeffry Evans, Thomas R., Läubli, Heinz, Roth, Patrick, Kristeleit, Rebecca, Brazil, Lucy, Tabatabai, Ghazaleh, Wick, Antje, Wunderlich, Benjamin, Beebe, Kirk, Eisner, Joel Robert, Lane, Heidi, Engelhardt, Marc, Kaindl, Thomas, Hau, Peter, Hundsberger, Thomas, Steinbach, Joachim
Format:	Journal Article
Language:	English
Published:	United States Elsevier Inc 17.06.2025 Elsevier
Subjects:	Administration, Oral Adult Advanced Basic Science Aged Antineoplastic Agents - administration & dosage Antineoplastic Agents - therapeutic use astrocytoma Biomarkers, Tumor - metabolism Brain Neoplasms - drug therapy Brain Neoplasms - pathology Dose-Response Relationship, Drug Female glioblastoma Glioblastoma - drug therapy Glioblastoma - metabolism Glioblastoma - pathology glioma Glioma - drug therapy Glioma - metabolism Glioma - pathology Humans lisavanbulin Male Middle Aged Neoplasm Grading glioma glioblastoma lisavanbulin astrocytoma
ISSN:	2666-3791, 2666-3791
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!